Sayenko Kharenko's antitrust team has provided legal
assistance in obtaining merger clearance with the Antimonopoly
Committee of Ukraine (the "AMC") for the
EUR 22.8 billion acquisition of Sanofi's animal health (AH)
business ("Merial") by Boehringer Ingelheim through an
asset swap in exchange for Boehringer Ingelheim's consumer
healthcare (CHC) business. The transaction is expected to close in
Q4 2016, subject to appropriate regulatory approvals globally.
The transaction would allow Sanofi to become a global leader in
consumer healthcare. Whereas combining Merial's and Boehringer
Ingelheim's complementary strengths would create the second
largest player in the global animal health market.
Boehringer Ingelheim is one of the world's
20 leading pharmaceutical companies. Headquartered in Ingelheim,
Germany, it operates globally through 146 affiliates and a total of
more than 47,700 employees. The focus of the family-owned company,
founded in 1885, is researching, developing, manufacturing and
marketing new medications of high therapeutic value for human and
veterinary medicine. Boehringer Ingelheim Consumer Healthcare is
the eighth largest consumer healthcare business in the world.
Sanofi, a global healthcare leader, discovers,
develops and distributes therapeutic solutions focused on
patients' needs. Sanofi is organized into five global business
units: Diabetes and Cardiovascular, General Medicines and Emerging
Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Merial is a
world-leading, innovation-driven animal health company. It has
three main business areas: pets, farm animals, and veterinary
public health. Its pharmaceuticals and vaccines target more than
200 diseases and conditions across a variety of species. Merial
employs 6,900 people and operates in more than 150 countries
After examining the proposed transaction, the AMC has concluded
that its implementation poses neither threat to competition nor
significantly limits competition on any product market in
Sayenko Kharenko's competition team advising on the project
included counsel Maksym Nazarenko, associates Julia Kuyda and Igor
Pomaz, and was led by partner Vladimir Sayenko.
Sayenko Kharenko enjoys global reputation as a leading
Ukrainian law firm with an internationally oriented full-service
practice. The firm's leading market position builds on
continuous excellence of its highly specialized practice teams.
During the past two years, Sayenko Kharenko collected three of the
most prestigious professional excellence country awards, more
specifically, Law Firm of the Year by each of IFLR European Awards,
Who's Who Legal European Awards and Chambers Europe Award for
Excellence. Most recently, Sayenko Kharenko was crowned Ukraine Law
Firm of the Year by Who's Who Legal 2016, and shortlisted in
Russia, Ukraine & the CIS category by The Lawyer European
Awards 2016 and Ukraine Law Firm of the Year category by Chambers
Europe Awards 2016.
To learn more about Sayenko Kharenko expertise and
experience, please contact
The competition law enforcement in Turkey is based on private and public enforcement pillars. TCA has sole discretion to enforce the Competition Act whereas the litigations initiated by the victims of anti-competitive conduct are seen in private courts.
Daiichi Sankyo İlaç Ticaret Ltd. Şti. ("Daiichi"), a globally active company in the distribution, sale, marketing and importation of pharmaceutical products, and Aksel Ecza Deposu A.Ş. ("Aksel"), a drug wholesaler, entered into a vertical exclusivity agreement ("Agreement").
The Competition Board concluded its investigation with regard to the booking services provided by Booking.com B.V. and by Bookingdotcom Destek Hizmetleri LLC, operating as the Turkish representative of Booking.com.
For the past few years, Turkey has tended to use various trade remedy tools more frequently, thus the number of investigations increases in depth and breadth with the aim of supporting domestic industry...
The CAT in the UK heard on 17 January 2017 an application by Flynn Pharma Ltd and Flynn Pharma (Holdings) Ltd to suspend the Competition and Markets Authority's direction to reduce the price of an epilepsy drug.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).